Bana Jobe

In the 1980s, researchers from the National Institutes of Health (NIH) recognized the potential of TIL and were the first to isolate them from mouse models. Iovance has since licensed the technology from the NIH to further study its applications in solid tumors, with the melanoma indication the first of many hoped for from the program.

Hosted by Bana Jobe, this podcast series explores the impact of AI on clinical care, and more specifically, how these tools are not just ambient scribes but trusted teammates that can answer questions, retrieve information, and automate everyday tasks.

The biopharmaceutical industry is advancing faster than ever — not just in the lab, but across commercial, operational, and policy spheres. That rapid evolution is reshaping how therapies are developed, delivered, and reimbursed. Yet that speed often runs into friction — from the lab to logistics. Challenges in economics, policies, supply chains, and market access can test even the best and most innovative science. As companies adapt their programs with these dynamics in mind, where should they place their bets next?

With mounting pressure to accelerate timelines, control costs and globalize trials, many sponsors are seeking streamlined, resilient, global testing solutions that will harmonize testing, enable rapid trial startup and reduce overall costs. In this playbook, we’ll explore how pharma organizations can do that, as well as how to find the right partner to get you there.

Uniquely situated as an independently-owned company, Boehringer is relatively insulated against short-term market fluctuations. That positioning gives researchers more room to follow their curiosities and pursue discoveries with a desire to serve humankind, less constrained by investor volatility. It’s a distinct advantage in a time of uncertainty felt elsewhere.

As pharma leaders explore a new world of AI-enabled RWE, they’re encountering pivotal questions: Where else can we go with this evidence we’re generating? And how do we govern it? Those are exactly the kinds of questions this whitepaper answers.

EHL is an acronym that hasn’t gotten much attention among providers, much less patients. But Chiesi, along with advocates from the American Lung Association (ALA), Allergy & Asthma Network (AAN), Asthma & Allergy Foundation of America (AAFA), and others, hope to change that.

Geopolitical uncertainty and policy shifts affecting traditional research hubs are driving life sciences companies to consider Canada's stable regulatory environment, robust site infrastructure, and proximity to major markets as key advantages for global trial strategies.

Continuing declines in HIV-related deaths show that modern advancements are on track. But while innovations are ongoing, access concerns persist; epidemics aren’t cured until everyone benefits.

Despite high awareness of AI and ML tools, some biopharma leaders may overlook opportunities to use automation as they take their programs to market. Inside this report, we’ll explore those potentially untapped areas as we unpack IPM.ai's latest survey results in the context of what’s next in a new era of AI-supported launch planning.

With an innovation pipeline across oncology, immunology, neuroscience, and beyond, Genentech has plans for an even bigger R&D impact over the next 50 years. The question, though, is access: Will everyone who needs this future care get it?

As more consumers embrace self-service as part of everyday life, it makes sense that patients would want that same experience from a hub program. How do your patient access and support services plan to evolve?

Biopharma organizations are exploring artificial intelligence across multiple use cases: patient identification, data analysis, regulatory submissions, and beyond. Along the way, they’re seeing both short- and long-term success; some changes are fast, and others are slow.

Pharma companies traditionally rely on payer coverage data, including formularies and restrictions, to understand the contours of their market access barriers. While these inputs are certainly valuable, they can create an incomplete picture. That’s why manufacturers are increasingly relying on real-world data (RWD) to uncover the blind spots in their market access analysis.

As healthcare in the US continues to decentralize, pharmacists can prepare for delivering more equitable care to patients in their community.